Cargando…

Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway

BACKGROUND: Tanshinone I (TI) is a primary component of Salvia miltiorrhiza Bunge (Danshen), which confers a favorable role in a variety of pharmacological activities including cardiovascular protection. However, the exact mechanism of the cardiovascular protection activity of TI remains to be illus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuo, Youqiong, Yuan, Renyikun, Chen, Xinxin, He, Jia, Chen, Yangling, Zhang, Chenwei, Sun, Kaili, Yang, Shilin, Liu, Zhenjie, Gao, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240219/
https://www.ncbi.nlm.nih.gov/pubmed/34183021
http://dx.doi.org/10.1186/s13020-021-00458-7
_version_ 1783715169280458752
author Zhuo, Youqiong
Yuan, Renyikun
Chen, Xinxin
He, Jia
Chen, Yangling
Zhang, Chenwei
Sun, Kaili
Yang, Shilin
Liu, Zhenjie
Gao, Hongwei
author_facet Zhuo, Youqiong
Yuan, Renyikun
Chen, Xinxin
He, Jia
Chen, Yangling
Zhang, Chenwei
Sun, Kaili
Yang, Shilin
Liu, Zhenjie
Gao, Hongwei
author_sort Zhuo, Youqiong
collection PubMed
description BACKGROUND: Tanshinone I (TI) is a primary component of Salvia miltiorrhiza Bunge (Danshen), which confers a favorable role in a variety of pharmacological activities including cardiovascular protection. However, the exact mechanism of the cardiovascular protection activity of TI remains to be illustrated. In this study, the cardiovascular protective effect and its mechanism of TI were investigated. METHODS: In this study, tert-butyl hydroperoxide (t-BHP)-stimulated H9c2 cells model was employed to investigate the protective effect in vitro. The cell viability was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay and lactate dehydrogenase (LDH) kit. The reactive-oxygen-species (ROS) level and mitochondrial membrane potential (MMP) were investigated by the flow cytometry and JC-1 assay, respectively. While in vivo experiment, the cardiovascular protective effect of TI was determined by using myocardial ischemia–reperfusion (MI/R) model including hematoxylin–eosin (H&E) staining assay and determination of superoxide dismutase (SOD) and malondialdehyde (MDA). Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) release were detected by Enzyme-linked immunosorbent assay (ELISA). Receptor interacting protein kinase 1 (RIP1), receptor interacting protein kinase 3 (RIP3), receptor interacting protein kinase 3 (MLKL), protein kinase B (Akt), Nuclear factor erythroid 2 related factor 2 (Nrf2), Heme oxygenase-1 (HO-1) and NAD(P)H: quinone oxidoreductase-1 (NQO-1) were determined by western blotting. RESULTS: Our data demonstrated that TI pretreatment attenuated t-BHP and MI/R injury-induced necroptosis by inhibiting the expression of p-RIP1, p-RIP3, and p-MLKL. TI activated the Akt/Nrf2 pathway to promote the expression of antioxidant-related proteins such as phosphorylation of Akt, nuclear factor erythroid 2 related factor 2 (Nrf2), quinone oxidoreductase-1 (NQO-1) and heme oxygenase-1 (HO-1) expression in t-BHP-stimulated H9c2 cells. TI relieved oxidative stress by mitigating ROS generation and reversing MMP loss. In vivo experiment, TI made electrocardiograph (ECG) recovery better and lessened the degree of myocardial tissue damage. The counts of white blood cell (WBC), neutrophil (Neu), lymphocyte (Lym), and the release of TNF-α and IL-6 were reversed by TI treatment. SOD level was increased, while MDA level was decreased by TI treatment. CONCLUSION: Collectively, our findings indicated that TI exerted cardiovascular protective activities in vitro and in vivo through suppressing RIP1/RIP3/MLKL and activating Akt/Nrf2 signaling pathways, which could be developed into a cardiovascular protective agent. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-021-00458-7.
format Online
Article
Text
id pubmed-8240219
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82402192021-06-29 Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway Zhuo, Youqiong Yuan, Renyikun Chen, Xinxin He, Jia Chen, Yangling Zhang, Chenwei Sun, Kaili Yang, Shilin Liu, Zhenjie Gao, Hongwei Chin Med Research BACKGROUND: Tanshinone I (TI) is a primary component of Salvia miltiorrhiza Bunge (Danshen), which confers a favorable role in a variety of pharmacological activities including cardiovascular protection. However, the exact mechanism of the cardiovascular protection activity of TI remains to be illustrated. In this study, the cardiovascular protective effect and its mechanism of TI were investigated. METHODS: In this study, tert-butyl hydroperoxide (t-BHP)-stimulated H9c2 cells model was employed to investigate the protective effect in vitro. The cell viability was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay and lactate dehydrogenase (LDH) kit. The reactive-oxygen-species (ROS) level and mitochondrial membrane potential (MMP) were investigated by the flow cytometry and JC-1 assay, respectively. While in vivo experiment, the cardiovascular protective effect of TI was determined by using myocardial ischemia–reperfusion (MI/R) model including hematoxylin–eosin (H&E) staining assay and determination of superoxide dismutase (SOD) and malondialdehyde (MDA). Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) release were detected by Enzyme-linked immunosorbent assay (ELISA). Receptor interacting protein kinase 1 (RIP1), receptor interacting protein kinase 3 (RIP3), receptor interacting protein kinase 3 (MLKL), protein kinase B (Akt), Nuclear factor erythroid 2 related factor 2 (Nrf2), Heme oxygenase-1 (HO-1) and NAD(P)H: quinone oxidoreductase-1 (NQO-1) were determined by western blotting. RESULTS: Our data demonstrated that TI pretreatment attenuated t-BHP and MI/R injury-induced necroptosis by inhibiting the expression of p-RIP1, p-RIP3, and p-MLKL. TI activated the Akt/Nrf2 pathway to promote the expression of antioxidant-related proteins such as phosphorylation of Akt, nuclear factor erythroid 2 related factor 2 (Nrf2), quinone oxidoreductase-1 (NQO-1) and heme oxygenase-1 (HO-1) expression in t-BHP-stimulated H9c2 cells. TI relieved oxidative stress by mitigating ROS generation and reversing MMP loss. In vivo experiment, TI made electrocardiograph (ECG) recovery better and lessened the degree of myocardial tissue damage. The counts of white blood cell (WBC), neutrophil (Neu), lymphocyte (Lym), and the release of TNF-α and IL-6 were reversed by TI treatment. SOD level was increased, while MDA level was decreased by TI treatment. CONCLUSION: Collectively, our findings indicated that TI exerted cardiovascular protective activities in vitro and in vivo through suppressing RIP1/RIP3/MLKL and activating Akt/Nrf2 signaling pathways, which could be developed into a cardiovascular protective agent. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-021-00458-7. BioMed Central 2021-06-28 /pmc/articles/PMC8240219/ /pubmed/34183021 http://dx.doi.org/10.1186/s13020-021-00458-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhuo, Youqiong
Yuan, Renyikun
Chen, Xinxin
He, Jia
Chen, Yangling
Zhang, Chenwei
Sun, Kaili
Yang, Shilin
Liu, Zhenjie
Gao, Hongwei
Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway
title Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway
title_full Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway
title_fullStr Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway
title_full_unstemmed Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway
title_short Tanshinone I exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via Akt/Nrf2 signaling pathway
title_sort tanshinone i exerts cardiovascular protective effects in vivo and in vitro through inhibiting necroptosis via akt/nrf2 signaling pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240219/
https://www.ncbi.nlm.nih.gov/pubmed/34183021
http://dx.doi.org/10.1186/s13020-021-00458-7
work_keys_str_mv AT zhuoyouqiong tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT yuanrenyikun tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT chenxinxin tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT hejia tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT chenyangling tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT zhangchenwei tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT sunkaili tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT yangshilin tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT liuzhenjie tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway
AT gaohongwei tanshinoneiexertscardiovascularprotectiveeffectsinvivoandinvitrothroughinhibitingnecroptosisviaaktnrf2signalingpathway